Nucleozin

Name: Nucleozin
Brand: MedChemExpress
SKU: HY-50001
Rating: 5.0 (6 reviews)

Cat. No.: HY-50001 Purity: 99.66%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Nucleozin, a potent inhibitor of influenza A virus infection, induces the formation of nucleoprotein (NP) aggregates and antagonizes its nuclear accumulation, leading to cessation of viral replication. Nucleozin impedes influenza A virus replication in vitro with a nanomolar EC₅₀.

For research use only. We do not sell to patients.

Nucleozin Chemical Structure

CAS No. : 341001-38-5

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 81	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 81	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 74	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 119	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 220	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 350	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 490	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

5 Publications Citing Use of MCE Nucleozin

: Nucleozin purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2017 Jul;143:106-112. [Abstract]; MDCK cells are infected with H1N1/09pdm at an MOI of 10 in the presence of DMSO, CAE (60 μM) or Nucleozin (1 μM). At 3 h later, cells are fixed by 4% paraformaldehyde and NP is detected by IFA. Nuclei are stained with DAPI. Immunofluorescence is observed with a Nikon A1 confocal microscope.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
MDCK	IC₅₀	> 100 μM Compound: 1	Antiviral activity against Influenza A virus A/New Jersey/8/76 (H1N1) expressing NP Y289H mutant infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/New Jersey/8/76 (H1N1) expressing NP Y289H mutant infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	> 50 μM Compound: 1	Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) harboring nucleoprotein 52H mutant infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) harboring nucleoprotein 52H mutant infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days	[PMID: 22332894]
MDCK	CC₅₀	> 80 μM Compound: Nucleozin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	IC₅₀	0.1 μM Compound: 1	Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as reduction in plaque formation after 3 days by microplate counting of infectious particles assay Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as reduction in plaque formation after 3 days by microplate counting of infectious particles assay	[PMID: 22332894]
MDCK	IC₅₀	0.15 μM Compound: 1	Antiviral activity against Influenza A virus A/RG14 (H5N1) harboring hemagglutininin and neuraminidase genes from Influenza A virus A/VietNam/1194/2004 and other influenza genes from PR8 viruses infected in MDCK cells assessed as inhibition of virus-induc Antiviral activity against Influenza A virus A/RG14 (H5N1) harboring hemagglutininin and neuraminidase genes from Influenza A virus A/VietNam/1194/2004 and other influenza genes from PR8 viruses infected in MDCK cells assessed as inhibition of virus-induc	[PMID: 22332894]
MDCK	IC₅₀	0.2 μM Compound: 1	Antiviral activity against Influenza A virus A/Weiss/43 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Weiss/43 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.32 μM Compound: 1	Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.34 μM Compound: 1	Antiviral activity against Influenza A virus A/udorn/1972 (H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/udorn/1972 (H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.49 μM Compound: 1	Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) harboring wild type nucleoprotein 52Y infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) harboring wild type nucleoprotein 52Y infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days	[PMID: 22332894]
MDCK	IC₅₀	0.52 μM Compound: 1	Antiviral activity against Influenza A virus A/Mal/302/54 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Mal/302/54 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.54 μM Compound: 1	Antiviral activity against Influenza A virus A/Guangzhou/2009 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Guangzhou/2009 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.66 μM Compound: 1	Antiviral activity against tamiflu-resistant Influenza A virus A/WSN/33 (H1N1) harboring neuraminidase 274Y mutant infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days Antiviral activity against tamiflu-resistant Influenza A virus A/WSN/33 (H1N1) harboring neuraminidase 274Y mutant infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days	[PMID: 22332894]
MDCK	EC₅₀	0.71 μM Compound: Nucleozin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	IC₅₀	1.08 μM Compound: 1	Antiviral activity against Influenza A virus A/HK/8/68(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/HK/8/68(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	1.59 μM Compound: 1	Antiviral activity against Influenza A virus A/Brisbane/10/2007 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Brisbane/10/2007 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	12.4 μM Compound: 1	Antiviral activity against Influenza A virus A/Brisbane/10/2007 (H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Brisbane/10/2007 (H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	CC₅₀	15.9 μM Compound: 1	Cytotoxicity against MDCK cells after 3 days by CCK-8 assay Cytotoxicity against MDCK cells after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	3.87 μM Compound: 1	Antiviral activity against Influenza A virus A/Guangdong/96 (H9N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Guangdong/96 (H9N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]

In Vitro

Nucleozin inhibits infection of MDCK cells by the viruses influenza A/WSN/33, H3N2 and Vietnam/1194/04 (H5N1) with an EC₅₀ of 0.069 μM, 0.16 μM and 0.33 μM in plaque reduction assay (PRA) , respectively, severely suppresses viral growth at 0.1 μM and totally inhibites virus production at 1 μM in multicycle growth assays^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nucleozin protectes mice challenged with lethal doses of avian influenza A H5N1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

426.85

Formula

C₂₁H₁₉ClN₄O₄

CAS No.

341001-38-5

Appearance

Solid

Color

Light yellow to yellow

SMILES

CC1=C(C(C2=CC=CC=C2)=NO1)C(N3CCN(C4=C(C=C(C=C4)[N+]([O-])=O)Cl)CC3)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL (46.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3427 mL	11.7137 mL	23.4274 mL
5 mM	0.4685 mL	2.3427 mL	4.6855 mL
10 mM	0.2343 mL	1.1714 mL	2.3427 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (4.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2 mg/mL (4.69 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.66%

Select Batch:

Data Sheet (276 KB) SDS (479 KB)

COA (252 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Kao RY, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28(6):600-605. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3427 mL	11.7137 mL	23.4274 mL	58.5686 mL
	5 mM	0.4685 mL	2.3427 mL	4.6855 mL	11.7137 mL
	10 mM	0.2343 mL	1.1714 mL	2.3427 mL	5.8569 mL
	15 mM	0.1562 mL	0.7809 mL	1.5618 mL	3.9046 mL
	20 mM	0.1171 mL	0.5857 mL	1.1714 mL	2.9284 mL
	25 mM	0.0937 mL	0.4685 mL	0.9371 mL	2.3427 mL
	30 mM	0.0781 mL	0.3905 mL	0.7809 mL	1.9523 mL
	40 mM	0.0586 mL	0.2928 mL	0.5857 mL	1.4642 mL

Nucleozin Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nucleozin341001-38-5Influenza VirusvirusinfectionviralreplicationnucleoproteinnuclearaccumulationInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Nucleozin

Customer Review

Nucleozin Related Antibodies

5 Publications Citing Use of MCE Nucleozin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Nucleozin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Nucleozin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report